利妥昔单抗治疗原发性肾病综合征患儿效果观察及长期随访结果分析  

Observation on the Effect of Rituximab in the Treatment of Children with Primary Nephrotic Syndrome and Analysis of Long-term Follow-up Results

作　　者：徐文莉 沈彤 谷松磊 曾煜闺 张琼伟 杨晓庆 XU Wenli;SHEN Tong;GU Songlei;ZENG Yugui;ZHANG Qiongwei;YANG Xiaoqing(Department of Pediatrics,Women and Children's Hospital,School of Medicine,Xiamen University/Xiamen Maternal and Child Care Hospital,Xiamen 361000,Fujian province,China)

机构地区：[1]厦门大学附属妇女儿童医院/厦门市妇幼保健院儿科学系儿内科,福建厦门361000

出　　处：《中国药物滥用防治杂志》2025年第2期308-310,共3页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：福建省自然科学项目(编号:3502Z202374019)。

摘　　要：目的:探究原发性肾病综合征患儿应用利妥昔长期随访的疗效与安全性。方法:回顾性分析了厦门市妇幼保健院2021年1月—2023年12月收治的40例原发性肾病综合征患儿为研究对象,通过治疗方法将其分为两组,对照组20例应用糖皮质激素治疗,观察组20例则在对照组基础上给予利妥昔单抗治疗,比较两组免疫功能指标、临床指标水平、不良反应发生情况。结果:观察组患儿经治疗后6个月、12个月IgA、IgM、C3、TC水平低于对照组,IgG、ALB水平高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:原发性肾病综合征患儿经过利妥昔单抗治疗可改善其免疫细胞水平,有效调节机体功能,长期随访具有良好的安全性、有效性。Objective:To explore the efficacy and safety of long-term follow-up of rituximab in children with primary nephrotic syndrome.Methods:A retrospective analysis of 40 children with primary nephrotic syndrome admitted to Xiamen Maternal and Child Health Hospital from January 2021 to December 2023 was conducted.They were divided into two groups by treatment methods.20 patients in the control group were treated with glucocorticoids.20 patients in the observation group were treated with rituximab on the basis of the control group.The immune function indexes,clinical index levels and adverse reactions were compared between the two groups.Results:The levels of IgA,IgM,C3 and TC in the observation group were lower than those in the control group at 6 months and 12 months after treatment,and the levels of IgG and ALB were higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Rituximab treatment in children with primary nephrotic syndrome can improve their immune cell levels and effectively regulate body function.Long-term follow-up has good safety and effectiveness.

关 键 词：利妥昔单抗 原发性肾病综合征 免疫功能 

分 类 号：R726.9[医药卫生—儿科]